|17.34||-1.12||-6.07%||Vol 1.94M||1Y Perf -69.23%|
|Aug 16th, 2022 16:00 DELAYED|
|- -||0.55 3.17%|
|Target Price||34.20||Analyst Rating||Hold 2.75|
|Potential %||97.23||Finscreener Ranking||★★ 46.09|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★+ 49.62|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★+ 48.73|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||12.22||Earnings Rating||Neutral|
|Market Cap||1.19B||Earnings Date||3rd Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.84|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.68M|
|Avg. Monthly Volume||1.71M|
|Avg. Quarterly Volume||1.67M|
Editas Medicine Inc. (NASDAQ: EDIT) stock closed at 17.34 per share at the end of the most recent trading day (a -6.07% change compared to the prior day closing price) with a volume of 1.94M shares and market capitalization of 1.19B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 235 people. Editas Medicine Inc. CEO is Cynthia Collins.
The one-year performance of Editas Medicine Inc. stock is -69.23%, while year-to-date (YTD) performance is -34.69%. EDIT stock has a five-year performance of -7.77%. Its 52-week range is between 9.59 and 73.025, which gives EDIT stock a 52-week price range ratio of 12.22%
Editas Medicine Inc. currently has a PE ratio of -7.00, a price-to-book (PB) ratio of 2.77, a price-to-sale (PS) ratio of 39.90, a price to cashflow ratio of 616.40, a PEG ratio of 2.32, a ROA of -27.60%, a ROC of -33.22% and a ROE of -34.20%. The company’s profit margin is -87.89%, its EBITDA margin is -566.00%, and its revenue ttm is $31.80 Million , which makes it $0.46 revenue per share.
Of the last four earnings reports from Editas Medicine Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.84 for the next earnings report. Editas Medicine Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Editas Medicine Inc. is Hold (2.75), with a target price of $34.2, which is +97.23% compared to the current price. The earnings rating for Editas Medicine Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Editas Medicine Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Editas Medicine Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 22.94, ATR14 : 1.37, CCI20 : 61.44, Chaikin Money Flow : 0.14, MACD : 1.13, Money Flow Index : 72.34, ROC : 12.56, RSI : 48.38, STOCH (14,3) : 65.91, STOCH RSI : 0.39, UO : 54.59, Williams %R : -34.09), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Editas Medicine Inc. in the last 12-months were: Bruce Eaton (Sold 2 705 shares of value $46 261 ), James C. Mullen (Sold 32 057 shares of value $1 017 012 ), Lisa Anne Michaels (Sold 1 568 shares of value $60 101 ), Mark S. Shearman (Sold 5 145 shares of value $51 745 ), Michelle Robertson (Sold 5 782 shares of value $120 549 )
Wed, 03 Aug 2022 23:46 GMT Editas Medicine (EDIT) Gets a Buy Rating from Chardan Capital- TipRanks. All rights reserved.
Sun, 08 May 2022 15:15 GMT Editas Medicine (EDIT) Gets a Hold Rating from SVB Securities- TipRanks. All rights reserved.
Fri, 06 May 2022 01:47 GMT Editas Medicine (EDIT) Gets a Hold Rating from RBC Capital- TipRanks. All rights reserved.
Fri, 06 May 2022 01:16 GMT Editas Medicine (EDIT) Receives a Hold from Barclays- TipRanks. All rights reserved.
Sun, 27 Feb 2022 10:50 GMT Editas Medicine (EDIT) Receives a Hold from RBC Capital- TipRanks. All rights reserved.
Sat, 26 Feb 2022 16:21 GMT Editas Medicine (EDIT) Gets a Hold Rating from Evercore ISI- TipRanks. All rights reserved.
Fri, 25 Feb 2022 11:03 GMT Editas Gains 10.1% as Q4 Results Surpass Estimates- TipRanks. All rights reserved.
Tue, 15 Feb 2022 14:41 GMT Editas Medicine (EDIT) Gets a Hold Rating from Leerink Partners- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.